Stockwinners Market Radar for October 07, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Chanson International Holding trading halted, news pending

19:50 EDT Vision Marine Technologies Inc trading halted, news pending

19:50 EDT A2Z Cust2Mate Solutions Corp trading halted, news pending

19:13 EDT Nuburu secures strategic $65M investment to accelerate commercialization - NUBURU "announced a comprehensive funding program of approximately $65 million, including $15 million of direct investment and $50 million equity line of credit. This funding represents a pivotal moment for NUBURU, enabling us to accelerate commercialization with predictable access to capital."

18:45 EDT Paychex CEO: We had solid results in Q1 - In an interview on CNBC's Mad Money, John Gibson said Paychex continues to show good margin expansion. "We're executing our post-pandemic strategy and it's resonating with customers." He noted that small businesses are continuing to have difficulty attracting quality employees. The Midwest has taken the leadership position in small business growth, he added.

17:30 EDT ADT Inc. announces 'unauthorized activity on the company's network' - In a regulatory filing, ADT stated, "ADT Inc. recently became aware of unauthorized activity on the company's network, and discovered an unauthorized actor had illegally accessed ADT's network using compromised credentials obtained through a third-party business partner. The company promptly took steps to shut down the unauthorized access, notified the third party its systems had been compromised, launched an investigation, and implemented counter measures intended to safeguard the company's information technology assets and operations. ADT has hired leading third-party cybersecurity experts to assist with the company's response to the incident, and is working closely with federal law enforcement. The company is also cooperating closely with its third-party business partner to address the incident. The company believes the unauthorized actor exfiltrated certain encrypted internal ADT data associated with employee user accounts during the intrusion. Based on its investigation to date, the company does not believe customers' personal information has been exfiltrated, or that customers' security systems have been compromised. ADT's containment measures have resulted in some disruptions to the company's information systems, and the company's investigation is at an early stage and ongoing."

17:19 EDT MDU Resources to replace Chuy's in S&P 600 at open on 10/11 - Darden Restaurants (DRI) is acquiring Chuy's Holdings (CHUY) in a deal expected to be completed soon, pending final closing conditions. MDU Resources (MDU) announced its intention to spin-off a company later this month.

17:14 EDT Deckers Outdoor CFO sells $1.53M in common stock - In a regulatory filing, Deckers Outdoor disclosed that its CFO Steven Fasching sold 9.2K shares of common stock on October 4th in a total transaction size of $1.53M.

17:06 EDT MoneyGram reports cybersecurity issue impacting certain customers - MoneyGram provided an update on its recent cybersecurity issue that affected certain of the company's systems. While the company continues to investigate the issue with the assistance of external cybersecurity experts and has been coordinating with law enforcement, MoneyGram's systems are back online and the company has resumed normal business operations. On September 27, MoneyGram determined that, in connection with this issue, an unauthorized third party accessed and acquired personal information of certain consumers between September 20 and 22, 2024. MoneyGram's investigation is in its early stages and the Company is working diligently to determine which consumers were affected by this issue. The types of impacted information varied by affected consumer and included names, contact information, dates of birth, national identification numbers, a limited number of Social Security numbers, copies of government-issued identification documents, other identification documents, bank account numbers, MoneyGram Plus Rewards numbers, transaction information and, for a limited number of consumers, criminal investigation information.

17:01 EDT Optinose names Terry Kohler as CFO - Optinose (OPTN) announced the appointment of Terry Kohler as CFO. Kohler was most recently the CFO for Verrica Pharmaceuticals (VRCA), a dermatology therapeutics company, where he supported commercial preparations for the launch of a topical treatment for molluscum contagiosum and research and development pipeline investments. Kohler is an experienced biotech finance leader with over 20 years of business experience.

16:37 EDT J&J says SunRISe-2 discontinued for 'not showing superiority vs. chemoradiation' - The company stated, "The SunRISe-2 study in patients with muscle-invasive bladder cancer (MIBC) who are not receiving radical cystectomy was a bold approach to disrupt the established standard of care in chemoradiation in this difficult-to-treat population.Following an Independent Data Monitoring Committee recommendation and pre-specified interim analysis, SunRISe-2 was discontinued for not showing superiority versus chemoradiation. Based on data presented, we are highly confident in TAR-200 as a transformative therapy for bladder cancer where innovative and bladder-sparing options are urgently needed. Data from the SunRISe-4 study recently presented at the 2024 European Society for Medical Oncology Congress show the potential of TAR-200 in MIBC and we will continue to pursue approaches to advance care in this setting. We are on target for the U.S. FDA filing of TAR-200 monotherapy (SunRISe-1) in non-muscle invasive bladder cancer in early 2025 with the SunRISe-3 and SunRISe-5 studies underway. We remain confident in the TARIS platform having $5B+ potential." Reference Link

16:33 EDT Pangaea Logistics to purchase equity ownership of Nordic Bulk Partners - Pangaea Logistics Solutions announced a definitive agreement to purchase the remaining 50% equity ownership of its consolidated subsidiary, Nordic Bulk Partners LLC, from HS Nordic LLC, for $17.2M in cash. Nordic Bulk Partners LLC was established in 2019 as a joint venture to construct four Ice Class 1A Post-Panamax dry bulk vessels. The transaction is expected to be completed by November 1, 2024 subject to customary closing terms and conditions. Upon the completion of the transaction, Pangea will own 100% of the equity in Nordic Bulk Partners. The terms of the Nordic Bulk Partners operating agreement include ownership put and call provisions, which have been negotiated and exercised a year earlier than originally stipulated. HS Nordic's 50% equity ownership was recorded on Pangaea's balance sheet as of June 30, 2024 as a long term liability of $16.6M, which will be extinguished as a result of this purchase

16:31 EDT Luna Innovations receives Nasdaq staff determination letter - Luna Innovations Incorporated announced that on October 1, 2024, it received a staff determination letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, due to the Company's failure to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission, Nasdaq has determined that the Company's securities will be scheduled for delisting from Nasdaq unless the Company requests an appeal of the determination to a Hearings Panel.

16:26 EDT Penn Entertainment up 5% at $19.50 after Q3 pre-announcement

16:26 EDT Penn Entertainment sees Q3 Retail Operations EBITDA at $465M-$475M - Penn Entertainment stated: "The Company expects third quarter 2024 Retail Operations Adjusted EBITDAR to be in the range of $465M to $475M. Estimated third quarter 2024 Retail Operations Adjusted EBITDAR was negatively impacted by approximately $10 million due to unfavorable hold rates within our Northeast segment and volume declines in our South segment associated with severe weather disruptions and hotel remodeling. As disclosed in our Form 10-Q for the quarter ended September 30, 2023, third quarter 2023 Retail Operations Adjusted EBITDAR was positively impacted by $14 million in business interruption proceeds related to Hurricane Laura, which was recorded in the South segment. The Company is raising its previously estimated Interactive Adjusted EBITDA range for the third quarter 2024 to $(100) million to $(90) million, up from our previous guidance of $(135) million to $(115) million. Better than expected hold driven by a higher parlay mix from our improving product and lower promotional expenses accounted for the upside."

16:22 EDT FirstEnergy, Dominion, American Electric reach joint planning agreement - FirstEnergy Corp. (FE), Dominion Energy Virginia (D) and American Electric Power (AEP) have entered into an innovative joint planning agreement to propose several new regional electric transmission projects across multiple states within the PJM footprint. The innovative collaboration comes at a time when efficient and cost-effective regional transmission development is essential and encouraged by the Federal Energy Regulatory Commission, the independent federal agency that regulates the interstate transmission of electricity. Power demand in the PJM region is growing at an unprecedented pace due to rapid expansion of energy-intensive industries such as data centers, the electrification of transportation and heating, and increased manufacturing onshoring. At the same time, the region's power generation mix is changing as legacy generation is retired and more renewables are added to the grid. The companies jointly proposed the projects through PJM's Regional Transmission Expansion Plan Open Window process in September. PJM is the regional transmission organization that coordinates the transportation of wholesale electricity across a 13-state region. The proposed projects include several new 765-kV, 500-kV and 345-kV transmission lines in Virginia, Ohio and West Virginia. The projects remain in the early stages of development. If selected by PJM, the companies would then undertake an extensive, multi-year process to select routes, perform environmental studies, engage with communities, obtain state and local permitting and build the projects. In addition to the joint proposals, each of the three companies have also submitted individual proposals for other transmission projects consistent with how each company has participated in past PJM open windows.

16:20 EDT China SXT Pharmaceuticals receives noncompliance notification from Nasdaq - China SXT Pharmaceuticals announced that on October 3, the company received a notification letter from Nasdaq notifying the company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2).

16:18 EDT TechnipFMC awarded iEPCI contract for BP Kaskida development - TechnipFMC (FTI) has been "awarded an integrated Engineering, Procurement, Construction, and Installation - or iEPCI - contract by BP (BP) for its greenfield Kaskida development in the Gulf of Mexico. The contract covers the design and manufacture of subsea production systems, including 20,000 psi (20K) standardized subsea trees and manifolds. The scope also includes the design, manufacture, and installation of subsea umbilicals, risers, and flowlines. The award follows an integrated Front End Engineering and Design study by TechnipFMC. For TechnipFMC, the contract is categorized as a "substantial" award, valued between $250M and $500M. This award was included in inbound orders in the third quarter of 2024."

16:17 EDT Medirom Healthcare acquires rehabilitation centers from Y's, Inc. - Medirom Healthcare announced that it is expanding into the rehabilitation industry. In doing so, Medirom established a wholly-owned subsidiary, Medirom Rehab Solutions Inc., which acquired all of the rehabilitation centers of Y's, Inc. Prior to the acquisition by Medirom Rehab Solutions Inc., Y's, Inc. owned and operated ten cerebral infarction rehabilitation centers in Tokyo and other major cities across Japan.

16:13 EDT Vincerx Pharma announces two complete responses in VIP943 study - Vincerx Pharma announced two complete responses in the ongoing first-in-human, Phase 1 dose-escalation study of VIP943, the company's next-generation antibody-drug conjugate, or ADC, being evaluated in relapsed/refractory acute myeloid leukemia, or AML, higher-risk myelodysplastic syndrome, or HR-MDS, and B-cell acute lymphoblastic leukemia, or B-ALL. The company also provided pipeline and corporate updates. The ongoing Phase 1 dose-escalation study of VIP943 has enrolled 22 patients to date across several escalating dose cohorts. These 22 patients represent a 'hard-to-treat' salvage population, which rarely responds to monotherapy. Nine patients have received at least three doses of an efficacious dose of VIP943. Of these nine patients, four remain on study. So far, one patient with relapsed AML has achieved complete remission with incomplete hematologic improvement and one patient with HR-MDS has achieved complete remission with limited count recovery based on international consensus response criteria. These response criteria are widely recognized as an approvable benchmark in AML and MDS studies, further underscoring the significance of these early results. As of August, VIP943 has shown favorable safety and tolerability, with no dose-limiting toxicities reported in 22 patients. Serious adverse events, or SAEs, have been consistent with expectations for this patient population. The most common SAEs included pneumonia and cellulitis and febrile neutropenia. Only one patient experienced a drug-related SAE. Target engagement has been demonstrated by binding of VIP943 to CD123+ peripheral blood blasts from patients with AML from the Phase 1 study. Maximal receptor occupancy of 84% was achieved in the highest dose cohort. Across all the cohorts, receptor occupancy was retained for less than 96 hours. Concurrent decreases in CD123+ peripheral blood blasts were also observed after dosing. These pharmacodynamic markers show that VIP943 is binding to and eliminating CD123+ malignant cells. Preliminary pharmacokinetic data continues to show low release of payload. The half-life of VIP943 is less than 96 hours, and no accumulation occurs with repeat dosing. These PK and PD results have prompted evaluation of twice weekly dosing of VIP943 as a potential "induction" regimen. Enrollment in the once weekly and twice weekly dosing cohorts is ongoing. The company anticipates providing another data update on the ongoing Phase 1 VIP943 study by the end of the year.

16:11 EDT Cannae Holdings, KDSA to acquire majority stake in Watkins - Cannae Holdings "announced an agreement to acquire a majority stake in The Watkins Company, a 156-year-old American heritage brand renowned for its high-quality flavoring products. This strategic investment aims to leverage the strengths of both Cannae and KDSA to drive growth and innovation for Watkins' fast-growing portfolio of flavoring products including spices, seasonings, and extracts. The current majority owner and Chairman, Mark Jacobs, will roll a significant equity stake into the transaction. The transaction is expected to close in October 2024."

16:08 EDT Benchmark Electronics names Bryan Schumaker as CFO - Benchmark Electronics announced the appointment of Bryan Schumaker as the company's CFO, effective October 8. Schumaker brings more than 20 years of financial and leadership experience across public and private sectors, driving growth, operational excellence, and strategic capital management. Schumaker's impressive track record as CFO within both the manufacturing and renewable energy sectors positions him as a key contributor to Benchmark's future success. In his most recent role as CFO of SOURCE Global, Schumaker played a key role in transforming the financial operations of the company, preparing it for public market readiness and leading the development of a global shared service center in Malaysia.

16:07 EDT Black Diamond CFO Fang Ni, CPO Elizabeth Montgomery to depart in restructuring - Black Diamond Therapeutics announced a corporate restructuring in an effort to focus resources on advancing lead program BDTX-1535 into pivotal development, and to extend the company's expected cash runway into Q2 2026. BDTX-1535 has demonstrated Phase 2 clinical activity across a broad spectrum of epidermal growth factor receptor mutations, or EGFRm, in patients with recurrent non-small cell lung cancer, or NSCLC. In Q1 2025, Black Diamond anticipates sharing initial Phase 2 data for BDTX-1535 in the frontline setting for patients with EGFRm NSCLC. Also in Q1, the company plans to present updated Phase 2 results for BDTX-1535 in patients with recurrent EGFRm NSCLC and a potential registration path in the recurrent setting based on feedback from the FDA. Black Diamond is actively seeking partnerships as it deprioritizes its BDTX-4933 program in RAF/RAS-mutant solid tumors. To enable focused investment in BDTX-1535, Black Diamond has also taken steps to optimize operations, including a reduction in force, while retaining core drug development and management expertise. As part of the restructuring, chief business officer and CFO Fang Ni and chief people officer, or CPO, Elizabeth Montgomery are departing the company. Erika Jones, senior VP of finance and principal accounting officer, has been appointed principal financial officer of the company. Cost savings from the restructuring and other actions described above are expected to be sufficient to fund operations into Q2 2026.

16:06 EDT Nuvation Bio names Philippe Sauvage CFO - Nuvation Bio announced the appointment of Philippe Sauvage as Chief Financial Officer. "We are excited to welcome Philippe to Nuvation Bio at such an important stage of our evolution," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "Philippe has successfully driven growth and led finance and operations teams across U.S., European, and Asian markets. Philippe's uniquely broad skillset is reflected in his senior positions in pharmaceutical, hospital and government organizations. His strategic vision and insights that span finance and operations, to commercial strategy and marketing, to government and hospital reimbursement and market access, will be invaluable as we transition to a commercial-stage organization in 2025."

16:01 EDT ZJK Industrial announces partnership with Nvidia, annual capacity of 10B units - ZJK Industrial (ZJK) posted on X: "We are proud to partner with NVIDIA (NVDA) as a leading AI Infrastructure Provider! Annual Capacity of 10 Billion Units." Reference Link

15:44 EDT Google says 'Epic verdict missed the obvious,' will appeal - Lee-Anne Mulholland, Vice President, Regulatory Affairs, stated in a Google (GOOGL) blog post: "Today, the court overseeing our ongoing U.S. legal proceedings with Epic Games ordered changes to Android and Google Play, requested by Epic. As we have already stated, these changes would put consumers' privacy and security at risk, make it harder for developers to promote their apps, and reduce competition on devices. Ultimately, while these changes presumably satisfy Epic, they will cause a range of unintended consequences that will harm American consumers, developers and device makers. These Epic-requested changes stem from a decision that is completely contrary to another court's rejection of similar claims Epic made against Apple - even though, unlike iOS, Android is an open platform that has always allowed for choice and flexibility like multiple app stores and sideloading. We are appealing that underlying decision and we will ask the courts to pause Epic's requested changes, pending that appeal." Investors in Epic Games include Tencent (TCEHY), KKR (KKR), Disney (DIS), and Sony (SONY).

13:38 EDT eXp World announces industry settlement regarding home seller lawsuits - In an 8K filing, eXp World said that, "On October 1, 2024, eXp World Holdings entered into a Settlement Term Sheet in 1925 Hooper LLC, et al. v. The National Association of Realtors et. al., Case No. 1:23-cv-05392- SEG (United States District Court for the Northern District of Georgia, Atlanta Division). This Settlement is also to resolve the pending litigation in additional lawsuits... The Settlement resolves all claims in the Lawsuits and similar claims on a nationwide basis against the Company and releases the Company, its subsidiaries and affiliates, and their independent contractor real estate agents in the United States from the Claims. By the terms of the Settlement, the Company agreed to pay a total settlement amount of $34.0 million into a qualified settlement fund. In addition, the Company agreed to make certain changes to its business practices. The Company intends to use available cash to pay the Settlement Amount, which is expected to be paid as follows: 50% within thirty business days after preliminary court approval of the Settlement, and 50% on or before the one-year anniversary of initial settlement payment, which amounts will be released from escrow subject to final court approval of the Settlement. The proposed Settlement remains subject to preliminary and final court approval and will become effective upon such final approval. The Settlement and any actions taken to carry out the Settlement are not an admission or concession of liability, or of the validity of any claim, defense, or point of fact or law on the part of any party. The Company continues to deny the material allegations of the complaints in the Lawsuits."

12:00 EDT Arcadium Lithium rises 30.2% - Arcadium Lithium is up 30.2%, or 93c to $4.01.

12:00 EDT Duckhorn Portfolio rises 102.6% - Duckhorn Portfolio is up 102.6%, or $5.54 to $10.94.

12:00 EDT HCI Group falls -15.3% - HCI Group is down -15.3%, or -$17.64 to $97.75.

11:43 EDT Ethan Allen begins recovery process at North Carolina distribution center - An Ethan Allen distribution center located in Old Fort, North Carolina, was recently impacted by the significant flooding caused by Hurricane Helene. The distribution center, which primarily focuses on shipping custom-made home furnishings to select wholesale customers, has not yet resumed daily shipping operations due to limited road accessibility for tractor trailers. Recovery efforts have already begun, including restoration of electricity and internet connectivity. The Company's major upholstery operations, which are located in central North Carolina, were not significantly disrupted by Hurricane Helene and are currently operating at normal capacity. Like many local businesses, Ethan Allen is managing the evolving situation at its Old Fort distribution center. Ethan Allen's vertically integrated structure and strong manufacturing base in North America, where 75% of its products are made, offers the Company the ability to reroute operations and minimize disruptions in service.

11:05 EDT Endeavour Mining 'not currently aware' of any plans to revoke mining permits - Endeavour Mining notes media reports following a radio interview with the President of Burkina Faso, Ibrahim Traore. The company said, "On 5 October President Traore spoke on Radio Burkina to commemorate two years of his Presidency. He discussed several topics including corruption, security, transport, agriculture and mining, including a reference to certain mining permits that may potentially be revoked. Endeavour remains a trusted partner to the Government of Burkina Faso and can confirm that it is not currently aware of any plans to revoke any of its mining permits. The Government remains supportive of Endeavour's position in country as evidenced by the recent successful settlement agreement that Endeavour signed, involving the State of Burkina Faso, in respect of the divestment of the Boungou and Wahgnion mines, for which Endeavour has now received the first $30m payment."

11:01 EDT Gilead presents additional data from PURPOSE 2 trial - Gilead Sciences announced additional data from its pivotal Phase 3 PURPOSE 2 trial, providing an overview of the efficacy and safety of twice-yearly lenacapavir, the company's injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. The new data are being presented during an oral abstract session on October 8 at the 5th HIV Research for Prevention Conference in Lima, Peru and follow the unblinding of the trial at interim analysis in September, which showed that twice-yearly lenacapavir reduced HIV infections by 96% compared to background HIV incidence and demonstrated superiority to once-daily Truvada for HIV prevention as pre-exposure prophylaxis, or PrEP. "These data reinforce that twice-yearly lenacapavir could be a highly effective and potentially game-changing HIV prevention choice that we have long hoped for in our efforts to end the HIV epidemic. PURPOSE 2 was intentionally designed to reflect the lives and locations of many people who are disproportionately affected by HIV around the world by focusing on gender, racial, ethnic and geographic diversity," said Colleen Kelley, MD, MPH, Professor of Medicine at Emory University and a PURPOSE 2 Principal Investigator.

10:34 EDT Clean Energy's Vermont Renewable Gas secures $1M USDA REAP grant - Clean Energy Technologies announced that Vermont Renewable Gas has been selected by the United States Department of Agriculture as one of its Rural Energy for America Program Grant recipients. Administered by the USDA's Rural Development Office, this current $1.05B initiative funded through the Inflation Reduction Act seeks to issue grants which spur economic development and catalyze rural prosperity by throughout the United States through six quarterly competitions. VRG was selected to receive $1M towards completion of VRG's Vermont Renewable Gas - Lyndon 2.2-megawatt renewable energy facility in Lyndon, Vermont.

10:04 EDT Liquidia says Supreme Court rejects United Therapeutics' petition - Liquidia Corporation (LQDA) announced that the United States Supreme Court has rejected United Therapeutics' (UTHR) petition for a writ of certiorari, which requested permission to appeal prior decisions which found that all claims of U.S. Patent No. 10,716,793 are unpatentable due to prior art. As a result, the decision by the Patent Trial and Appeal Board in July 2022, which was affirmed by the U.S. Court of Appeals for the Federal Circuit in December 2023, is now final and not subject to further appeal. On August 16, 2024, the U.S. Food and Drug Administration granted tentative approval of YUTREPIA inhalation powder to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. In doing so, FDA confirmed that the amendment to add PH-ILD to the YUTREPIA New Drug Application was proper and that application otherwise meets the requirements for approval under the Federal Food, Drug, and Cosmetic Act. Final approval of YUTREPIA for PAH and PH-ILD may occur after expiration of 3-year regulatory exclusivity for Tyvaso DPI on May 23, 2025. There are no patents that are preventing final FDA approval of YUTREPIA. None of the valid claims of the three patents asserted by UTHR in original Hatch-Waxman litigation have been found to be infringed. All of the decisions are final and not subject to further appeal. Additionally, the U.S. District Court of the District of Delaware denied UTHR's request for a preliminary injunction with respect to a fourth patent, U.S. Patent No. 11,826,327 in a separate patent lawsuit filed by UTHR in September 2023. A trial in the '327 Patent lawsuit is scheduled for June 2025.

10:01 EDT Constellium, ISN partner for contractor management in North America - ISN announced that Constellium has selected ISNetworld as its primary contractor information management platform. ISN will assist Constellium with streamlining all aspects of its contractor management processes in North America, including online training, badging and scanning at its sites, and Training Qualifications

10:00 EDT Mytheresa rises 24.6% - Mytheresa is up 24.6%, or $1.06 to $5.37.

10:00 EDT Duckhorn Portfolio rises 101.4% - Duckhorn Portfolio is up 101.4%, or $5.47 to $10.88.

10:00 EDT Universal Insurance falls -16.6% - Universal Insurance is down -16.6%, or -$3.49 to $17.51.

09:58 EDT GDEV Inc trading resumes

09:49 EDT Mytheresa rises 25.1% - Mytheresa is up 25.1%, or $1.08 to $5.39.

09:48 EDT Duckhorn Portfolio rises 101.3% - Duckhorn Portfolio is up 101.3%, or $5.47 to $10.87.

09:47 EDT Torrid falls -11.0% - Torrid is down -11.0%, or -39c to $3.16.

09:44 EDT GDEV Inc trading halted, volatility trading pause

09:37 EDT Arcadium Lithium jumps 38% to $4.26 after Rio Tinto takeover approach

09:36 EDT Chanson International Holding trading halted, volatility trading pause

09:31 EDT LASER PHOTONICS CORPORATION trading halted, volatility trading pause

09:29 EDT Skyx Platforms announces completion of $11M strategic investment - SKYX Platforms announced the completion of a strategic investment of $11 million of a new class of preferred stock in SKYX, with a conversion price of $2.00 per common share, with an 8% annual dividend, led by Lance Shaner, Chairman & CEO of Shaner Hotel Group, joined by other strategic and key SKYX investors

09:27 EDT Ainos advances innocations with AI Nose, VELDONA technologies - Ainos continues to push the boundaries of global smart healthcare and immunotherapy innovation. The company said, "With its AI Nose and VELDONA low-dose oral interferon technologies, Ainos is not only spearheading advancements in medical technology but also demonstrating significant potential for industrial safety and automation applications. The Company's excellent research and development progress aligns with its strategic plans, with certain projects being completed ahead of schedule, showcasing Ainos' exceptional ability in both technology deployment and commercialization...Ainos has cemented its leadership in the fields of smart healthcare and immunotherapy through its dual innovations: AI-powered electronic nose technology and VELDONA low-dose oral interferon. With excellent progress in research and development, and ahead-of-schedule project completion, the Company continues to demonstrate its technological prowess. Moving forward, Ainos plans to expand the application of its technologies, playing a key role in driving global advancements in smart healthcare and industrial automation."

09:23 EDT Global Industrial enters partnership with NY Islanders, UBS Arena - Global Industrial Company announced a multi-year marketing partnership with the New York Islanders and UBS Arena. The partnership expands the Company's sports marketing program and enhances its ability to drive brand awareness and deepen customer engagement to both local and national audiences. With the new partnership, Global Industrial will feature its The Source For Industrial Supplies tagline through branding initiatives at all Islanders home games held at the state of the art UBS Arena at Belmont Park, as well as at the Northwell Health Ice Center practice facility. Global Industrial will sponsor the Islanders' Ice Crew through branded gear and essential ice removal and clearing equipment, to help maintain the world-class ice conditions. In addition, Global Industrial will partner with the Islanders to support community philanthropy events that benefit the Islanders Children's Foundation, promote girls' youth hockey, and recognize military service members along with their support organizations. Global Industrial will also participate in the UBS Arena Business Alliance, an exclusive membership network of team and arena partners.

09:22 EDT Euroseas announces one-year charter contract for M/V Jonathan P - Euroseas announced a time charter contract for its 1,732 teu feeder containership, M/V Jonathan P, for a minimum period of 11 to a maximum period of 13 months at the option of the charterer, at a gross daily rate of $20,000. The new charter will commence after the completion of her scheduled intermediate survey, expected around mid-to-end of October 2024.

09:21 EDT Freddie Mac announces tender offer for certain STACR notes - Freddie Mac has commenced a fixed-price cash tender offer for the purchase of any and all of the STACR Notes beginning Monday, October 7, 2024. Certain of the classes of Notes subject to the Offer were issued by the STACR Trust. Freddie Mac is the holder of the owner certificate issued by each Trust and, as a result, the sole beneficial owner of each Trust. Freddie Mac has engaged Wells Fargo Securities, LLC and StoneX Financial Inc. as lead dealer managers and CastleOak Securities, L.P. as co-dealer manager for the Offer. Freddie Mac is offering to purchase any and all of the Notes listed. The applicable Total Consideration to be paid by Freddie Mac to holders that tender Notes accepted for purchase pursuant to the Offer will be calculated based on the original principal amount of such tendered and accepted Notes, the applicable factor, and the applicable Tender Offer Consideration identified in the table below, plus any accrued and unpaid interest under the applicable Debt Agreement or Indenture upon the terms and subject to the conditions set forth in the Offer to Purchase dated October 7, 2024 and related Notice of Guaranteed Delivery dated October 7, 2024. Capitalized terms used and not otherwise defined herein will have the meaning ascribed to such terms in the Offer to Purchase. The tender offer period will commence on Monday, October 7, 2024, and expire at 5 p.m., New York City time, on Friday, October 11, 2024 unless extended. Holders must validly tender their Notes at or prior to the Expiration Time. Notes validly tendered may be withdrawn at any time at or prior to 5 p.m., New York City time, on Friday, October 11, 2024, unless extended by Freddie Mac, but not thereafter.

09:18 EDT Inspirato CFO Robert Kaiden to depart, Michael Arthur to succeed - Inspirato announced the promotion of Michael Arthur to CFO. Robert Kaiden, the current CFO, has planned to transition out of the role effective November 8, 2024. The Company also named three new members to its Board of Directors. Arthur joined Inspirato in February 2023 and has served as Senior Vice President of Finance, overseeing Corporate Finance, FP&A and Treasury. Prior to Inspirato, he spent more than 10 years in finance, accounting, and corporate strategy roles at PwC and VF Corporation. He will replace current CFO, Robert Kaiden, effective November 8, 2024. In addition to Mr. Zamani taking over as the Chairman of the Board of Directors, in the third quarter, the Company appointed three new members to its Board of Directors, including current Inspirato President David Kallery. The other two new members joining Inspirato's Board of Directors include: Julie Wainwright, Founder and former CEO of The RealReal. May Samali, Founder & CEO of Human Leadership Lab.

09:15 EDT T2 Biosystems enters exclusive U.S. agreement with Cardinal Health - T2 Biosystems (TTOO) has entered into a multi-year exclusive U.S. agreement with Cardinal Health (CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems' FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx Instrument, the T2Bacteria Panel, and the T2Candida Panel.

09:11 EDT Brand Engagement Network completes data integration with Dealer.com - Brand Engagement Network announced the completion of its data integration with Cox Automotive. This collaborative integration aims to address industry challenges in the automotive space. BEN's data integration allows Cox Automotive to harness the power of BEN's human-like AI Assistants as multimodal conversational resources tailored for unique purposes. These assistants are designed to help customers and enhance professionals to improve customer interactions and experiences. The AI Assistants are accessible on Dealer.com websites as an app and web browser, plus they can also be deployed through life-size kiosks in automotive settings to provide a seamless experience from the web to the dealership.

09:09 EDT Nokia, NTT Data expand global Private 5G partnership - Nokia has announced a global go-to-market partnership with NTT DATA, to advance Private 5G transformation in key sectors such as airports and smart cities. The collaboration addresses the growing need and demand for reliable and modern connectivity solutions for critical business and municipal operations and is already demonstrating success with key customers. The first North American deployment is an enterprise-ready, carrier-grade Private 5G Radio Access Network for the City of Brownsville, marking a key milestone for the collaboration. The City of Brownsville leverages Nokia's leading 5G radio access portfolio and NTT DATA's globally available Private 5G Network-as-a-Service platform, which delivers a comprehensive, turnkey solution that goes beyond connectivity to deliver exceptionally reliable, high-bandwidth, low-latency wireless capabilities for their mission-critical environments.

09:07 EDT GMC joins Electrify Expo lineup as exhibitor for 2024 season - Electrify Expo announced that GMC will join its impressive lineup of exhibitors for the remainder of the 2024 season. The addition of GMC offers attendees yet another sought-after brand to interact with and underscores the fun, consumer-centric approach Electrify Expo has to offer. GMC will join Electrify Expo at its final two locations for 2024, New York October 12-13, and Austin, TX November 9-10. GMC will showcase its growing portfolio of EVs, including ride and drive demos with the HUMMER EV Pickup and SUV, and display of the all-new Sierra EV. Festival goers will have the unique opportunity to feel the thrill of these electric models through immersive hands-on experiences designed to demystify the technology and amplify the excitement of electric vehicles.

09:06 EDT Amentum awarded $256M NASA contract - Amentum was awarded the Fully Integrated Lifecycle Mission Support Services II contract by NASA with a maximum value of $256M to spearhead cutting-edge technologies and manage groundbreaking science projects in support of NASA's exploration and aeronautics objectives at the Ames Research Center. Through this partnership, Amentum will introduce advanced project management tools that will enhance NASA's capabilities in space science and exploration.

09:05 EDT Montauk Renewables enters pilot agreement with Emvolon - Emvolon announced an agreement with Montauk Renewables, a renewable energy company specializing in the management, recovery and conversion of biogas from waste into renewable natural gas. Leveraging Emvolon's patented technology, the initial pilot is a commercial-scale demonstration of recovering and converting biogas into green methanol, which is expected to take place at Montauk's renewable gas production site at a landfill in Humble, Texas.

09:04 EDT LPL Financial: Morristown Wealth joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Don Giovanello, Jr., and Gian Paolella, CFP, with Morristown Wealth Management have joined LPL Financial's broker-dealer, RIA and custodial platforms. They reported having served approximately $340 million in advisory and retirement plan assets and join LPL from Raymond James Financial Services. The Morristown, N.J., -based family practice was established in 2009 by Don Giovanello, Sr., a beloved advisor who sadly lost his battle to cancer in 2018. His son, Don Jr., grew up immersed in the business and joined the practice in 2010 right out of college. He credits his father as a mentor and the driving inspiration for his career path and unwavering work ethic. Gian, who is Don, Jr.'s brother-in-law, is partner in the firm, joining in 2018 following an initial career in investment product sales. Rounding out the group is longtime practice manager Ellen Luithle, who started her career 25 years ago working alongside Don Sr. and continues to be an integral part of the team.

09:03 EDT CleanSpark says 'normal operations have resumed' after Hurricane Helene - CleanSpark announced normal operations have resumed after 365 MW of power was shut down in the wake of Hurricane Helene. The company's hashrate has since reached 28.7 EH/s.

09:00 EDT Dominari Holdings appoints James Hopkins as MD, head of capital markets - Dominari Holdings has further expanded its practice with the appointment of capital markets veteran James Hopkins as Managing Director Head of Capital Markets. Mr. Hopkins brings over three decades of capital markets and investment banking experience to Dominari. He has led and structured hundreds of transactions during his career over a broad range of financial instruments ranging from debt, equity, IPOs, secondary offerings, bridge financings and PIPEs. Most recently, he served as Head of Capital Markets at Dawson James Securities, where he spent more than 10 years originating, structuring and placing the firms' offerings.

08:56 EDT Kronos Bio nominates development candidate for Sjogren's Disease - Kronos Bio announced the nomination of a development candidate, KB-7898, a p300 lysine acetyltransferase inhibitor for the potential treatment of Sjogren's disease, a chronic autoimmune disease that is characterized by the production of autoantibodies, chronic inflammation and lymphocytic infiltration of the exocrine glands that lead to uncomfortable dryness symptoms, known as sicca. Systemic effects are common and impact the lungs, kidneys and nervous system in addition to extensive dryness, profound fatigue and chronic pain. There are no approved treatments that target the underlying cause of Sjogren's disease. Kronos Bio plans to initiate Investigational New Drug-enabling studies of KB-7898 in the fourth quarter of 2024. KB-7898 is being developed as an orally available therapy for people with Sjogren's disease. p300 is an important cofactor for interferon regulatory factor 4 to enact immune responses across multiple cell types, including those that produce antibodies and cytokines. Given this, Kronos Bio also intends to explore the utility of KB-7898 in other autoimmune diseases in the future. The Company's preclinical data that support the role of p300 in inflammatory indications, including Sjogren's disease, will be presented at the American College of Rheumatology's annual meeting, ACR Convergence 2024, on November 18, 2024, in Washington, DC. The data are summarized as follows: Inhibition of the KAT activity of p300, a critical cofactor of proinflammatory transcription factors, resulted in selective downregulation of cytokines such as TNFalpha, IL-23, IL-17A as well as soluble IgG Selective gene expression changes occurred at doses corresponding to partial inhibition of p300 KAT activity p300 KAT inhibition also led to significantly decreased inflammation in the rat CIA model, as measured by joint swelling, clinical score and histopathology In addition, p300 KAT inhibition in vitro showed a reduction in IL-17 transcript and protein levels in Th17 cells and, in vivo, showed significant decreases in the secondary immune response in the KLH challenge model.

08:53 EDT Inozyme appoints Erik Harris to board of directors - Inozyme Pharma, Inc. (INZY) announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx (RARE), brings to Inozyme over 20 years of commercial expertise within the biopharma industry.

08:51 EDT Telos expands enrollment, renewal options by opening twelve locations - Telos Corporation continues to expand locations to enroll consumers in the TSA PreCheck program by opening twelve new locations in California, Florida, Illinois, Mississippi, North Carolina, Oklahoma, Oregon, Texas and West Virginia. These locations will begin offering enrollment services today, October 7, 2024. Telos now has 137 TSA PreCheck enrollment centers open in 28 states across the U.S. The launch of these new enrollment centers represents the ongoing expansion of Telos' national TSA PreCheck enrollment footprint. Throughout 2024, Telos will continue delivering convenience to consumers by launching additional locations and extended hours of operation for enrollment and renewals.

08:50 EDT Galecto determines not to further advance GB2064 - Galecto continues to develop GB1211, its first-in-class, oral small molecule, galectin-3 inhibitor for the treatment of oncology and severe liver cirrhosis. GB1211 is currently being studied in an investigator-initiated Phase 2 trial at Providence Portland Medical Center's Earle A. Chiles Research Institute. GB1211 is being administered in combination with the standard therapeutic dose of pembrolizumab in patients with unresectable or metastatic melanoma or recurrent or metastatic HNSCC progressing during or after platinum-containing chemotherapy. This trial is designed to evaluate the safety and efficacy of GB1211 in combination with pembrolizumab and determine whether the addition of GB1211 increases the response rate of pembrolizumab in metastatic melanoma and HNSCC patients. This trial was initiated and enrolled its first patient in the second quarter of 2024. In addition, during the second half of 2023, Galecto concluded its Phase 1b/2a trial examining GB1211 in combination with atezolizumab, a PD-L1 checkpoint inhibitor, for the treatment of first-line non-small cell lung cancer. Four patients in this trial showed a partial response according to RECIST criteria (version 1.1), and two of these four patients continue to receive treatment in the extension phase of the trial. As part of the strategic alternative review process, Galecto has determined not to further advance GB2064, its LOXL-2 inhibitor candidate, at this time.

08:47 EDT Galecto completes strategic review, will focus on oncology, liver disease - Galecto (GLTO) announced that, following an intensive strategic review process, Galecto has determined to focus on cancer and liver disease, leveraging its existing clinical stage asset GB1211, which has shown positive results in non-small cell lung cancer and decompensated cirrhosis clinical studies. Galecto further announced that it has bolstered its pipeline with the acquisition of the global rights to BRM-1420, a novel, first-in-class asset developed by Bridge Medicines, a company co-founded by Takeda (TAK). "Our strategic review process concluded that our best opportunity for building value and changing the lives for patients with severe diseases was to focus on our existing clinical stage compound GB1211 and increase our chance for success by acquiring complementary assets. The addition of BRM-1420 represents a significant advancement in our mission to develop and deliver breakthrough treatments for oncology and liver conditions," said Dr. Hans Schambye, CEO of Galecto. "We are particularly optimistic about BRM-1420's potential to address challenging genetic subsets of AML and its observed synergistic effects with standard-of-care therapies and menin inhibitors." As consideration for the acquisition of the global rights of BRM-1420, Galecto issued 62,594 shares of common stock to Bridge Medicines, representing 4.99% of the outstanding shares of Galecto's common stock as of the date of the asset purchase, and 160.562 shares of a newly-issued Series A preferred stock convertible into 160,562 shares of common stock, or approximately 12.8% of Galecto's common stock, upon receipt of stockholder approval. Matthew Kronmiller, Bridge Medicine's Chief Executive Officer, will be joining Galecto's management team as the Executive Vice President of Strategy and Chief Business Officer. The transaction was approved by the Boards of Directors of both companies.

08:42 EDT Barfresh Food Group commences sales of 'Pop & Go' freeze pops - Barfresh Food Group has commenced selling its new 100% juice freeze pop, "Pop & Go", to the education channel. The Company expects to start generating revenue from Pop & Go in the fourth quarter of this year. Pop & Go contains a half-cup of fruit juice, no added sugars, no preservatives, artificial flavors or colors, and is compliant with USDA reimbursable meal programs and Smart Snack compliant. This new item complements the Company's existing school offerings, including 1:1 bulk easy pour, 5:1 juice concentrates, and Twist & Go products.

08:40 EDT Inspired Entertainment to showcase solutions at G2E - Inspired Entertainment is set to showcase its latest advancements at the Global Gaming Expo at the Venetian in Las Vegas, Nevada from October 10-12. The Company is excited to highlight the drivers behind its transformation of the gaming experience. The Hybrid Dealer product line represents a standout innovation in gaming, blending the best elements of traditional live dealer experiences with the efficiency and scalability of RNG technology. Unlike traditional live dealer setups, Inspired's Hybrid Dealer games do not need physical studios. By integrating computer-generated imagery, green screen technology, and authentic footage of real dealers, Inspired delivers a dynamic gaming experience made possible by their proprietary technology. In addition to showcasing new Hybrid Dealer games, Inspired will unveil its new Valiant portrait cabinet, designed specifically for North American route markets. This advanced cabinet boasts a larger display area, a user-friendly interface, and stunning 4K resolution, creating a compelling experience for players. With G2S-ready compatibility and an array of extensively tested content, the Valiant cabinet represents a significant enhancement for operators and slot players in Illinois.

08:38 EDT Expion360 announces 1-for-100 reverse stock split - Expion360 announced that its Board of Directors authorized the stockholders approved 1-for-100 reverse stock splitof its common stock, par value $0.001 per share. The Reverse Stock Split will become effective at 5:00 p.m. Pacific Time on October 8, 2024. The Common Stock will continue to trade on The Nasdaq Capital Market under the symbol "XPON" and will begin trading on a post-split basis when the market opens on October 9, 2024. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 30218B 209. The Reverse Stock Split is intended to enable the Company to regain compliance with the minimum bid price requirement for continued listing on Nasdaq.

08:36 EDT Luokung Technology regains compliance with Nasdaq minimum bid price rule - Luokung Technology received a letter from the Nasdaq Stock Market notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement. The letter noted that as of September 30, 2024, the Company evidenced a closing bid price of its ordinary shares at or greater than the $1.00 per share minimum requirement for 10 consecutive business days. Nasdaq stated that accordingly, Luokung has regained compliance with Nasdaq Marketplace Rule 5550(a)(2), and Nasdaq considers the matter closed.

08:34 EDT Newton Golf introduces Newton Motion shafts with high swing speeds - NEWTON GOLF announces the release of its latest innovation - the advanced Newton Motion shafts designed specifically for golfers with higher swing speeds. Building on the success of the original Newton Motion shafts, which feature a flex system ranging from the most flexible shaft at 1-dot to the stiffest at 6-dots, the new driver and fairway woods shafts extend the flex scale with the introduction of 6.5-dot and 7-dot options. The new models have been engineered to meet the demands of elite players, including professionals on the PGA Tour, Korn Ferry Tour, and Champions Tour, as well as top collegiate golfers. Each shaft is tailored to offer precise control, enhanced feel, and greater performance for high-speed swings.

08:34 EDT Trinity Biotech announces trial results for next-gen CGM technology - Trinity Biotech announced the completion of its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monito technology. The study assessed the analytical performance of CGM technology enhancements implemented by Trinity Biotech since acquiring the technology from Waveform Technologies in January 2024. "We have made significant progress in the development of our next generation factory-calibrated CGM, combining a high degree of accuracy with a unique modular design that simplifies and enhances user experience, while significantly reducing cost and waste," stated John Gillard, President and Chief Executive Officer of Trinity Biotech. "The outcome of this pre-pivotal study confirms the effectiveness of the R&D plan executed since the acquisition of the Waveform Technologies assets earlier this year and will be used to guide further sensor design optimisations." Trinity Biotech implemented a research and development plan aimed at improving both the performance and usability of the CE-marked, 15-day wear CGM device. Key design modifications introduced in this study include a significant reduction in the biosensor wire length, a change aimed at enhancing in-body performance. The trial results demonstrated that the refined sensor achieved a mean absolute relative difference (MARD) that compares favourably to the previous Waveform device.

08:33 EDT Ocean Power confirms shipment of Merrows PowerBuoy for Middle East - Ocean Power has received customer confirmation to ship to a customer in the Middle East the previously announced shipment ready AI capable Merrows PowerBuoy.

08:31 EDT Eco Wave Power signs agreement for sale of wave energy generation unit with I-Ke - Eco Wave Power announced that it signed an agreement for the sale of the first wave energy generation unit with I-Ke International Ocean Energy Co., a subsidiary of Lian Tat Company, a maritime engineering company, with the purpose of bringing Eco Wave Power's wave energy technology to Taiwan. According to the terms of the agreement, I-Ke will be providing the full financing for the 100KW pilot project, by buying a turnkey conversion unit from Eco Wave Power. This conversion unit for the 100KW wave energy power station includes all the hydraulic and electric conversion parts, coupled with the smart control and automation system. I-Ke has identified the location for the first pilot station of 100KW installed capacity on the east coast of Taiwan (along with an additional 83 potentially suitable sites) and it is responsible for obtaining permits, land use consents and any licensing and approvals necessary to complete the installation of the planned wave energy projects. Moreover, I-Ke will locally produce the floaters, hydraulic cylinders and all other components of the technology, which are located on the seaside of the marine structure. I-Ke believes this will position Taiwan as the hub for later stage expansion into other Asia Pacific regions. This newly signed agreement, which is based on a memorandum of understanding that was signed between Lian Tat and Eco Wave Power in June 2023, will leverage Eco Wave Power's wave energy conversion technology, which has been deployed in several locations worldwide, to maximize energy extraction and optimize the project's performance for the Taiwanese coastline. According to a press statement made by I-Ke, the first stage of the project will be the development of a 20 MW wave energy power station in Taiwan, beginning with a 100KW pilot and expanding in stages to a total targeted installed commercial capacity of 400 MW.

08:30 EDT Wearable Devices announces 1-for-20 reverse stock split - Wearable Devices intends to effect a one-for-twenty reverse split of the Company's ordinary shares, no par value per share and the Company's tradable warrants. The Ordinary Shares and Warrants will continue to trade on the Nasdaq Capital Market under the existing symbols "WLDS" and "WLDSW", respectively, and will begin trading on a split-adjusted basis when the market opens on October 10, 2024. The new CUSIP numbers for the Ordinary Shares and Warrants following the Reverse Share Split will be M97838 128 and M97838 151, respectively. The Reverse Share Split was approved by the Company's shareholders at the Company's Annual and Special Meeting of Shareholders held on September 26, 2024, to be effected at the board of directors' discretion within approved parameters, and the board of directors has approved the 1-for-20 ratio. The Reverse Share Split will not result in an adjustment to the authorized share capital of the Company under the Company's amended and restated articles of association, as currently in effect, which, as of the date hereof consists of 50,000,000 Ordinary Shares.

08:24 EDT Cerence CEO Stefan Ortmanns to depart, Brian Krzanich to succeed - Cerence announced that Brian Krzanich has been appointed CEO and a member of the Board of Directors, effective immediately. Mr. Krzanich succeeds Stefan Ortmanns, who is departing as CEO and resigning as a member of the Board. Most recently from 2018 to 2022, Mr. Krzanich served as CEO of CDK Global Inc., a supplier of software to the retail automotive industry.

08:22 EDT NIP Group appoints Randy Hearst Harris to board of directors - NIP Group announced the appointment of Randy Hearst Harris as an independent director to its Board of Directors, effective September 24, 2024. Mr. Harris, founder of the sports management company 3V, brings a wealth of experience to NIP Group's Board.

08:20 EDT Bionomics CEO believes company has 'significant, unrealized value' - Bionomics announced that Spyridon "Spyros" Papapetropoulos M.D., Ph.D., President and Chief Executive Officer of Bionomics, issued a letter to Bionomics shareholders, which read in part, "This year continues to be a pivotal year for Bionomics, characterized by numerous wins and essential changes that have enhanced the Company and furthered our goal of creating therapies for the countless individuals suffering from anxiety and stress disorders...Additionally, we are in the final stages of redomiciling the Company to the U.S. and launching Neuphoria Inc, a company with new vision, strategy and CNS pipeline focus to fully leverage the strong U.S. biotechnology ecosystem, while maintaining our Australian presence and potential future tax benefits. During the ordinary course of this process, we plan to consolidate our issued shares of our trading securities and remain compliant with the NASDAQ Stock Market listing rules. Thanks to these efforts, we believe the company is and will be fundamentally in a much stronger position today and moving forward. As shareholders ourselves, we remain disappointed in Bionomics' stock performance, particularly following our Annual Report filling on September 30, 2024. Yet, we believe that Bionomics is significantly undervalued, given our lead asset BNC210 is essentially a novel, "pipeline in a pill", small molecule with unique anxiolytic and antidepressant properties that can bring tremendous benefits to patients suffering from anxiety and stress disorders globally. Following the recent unfavorable industry developments with psychedelics in post-traumatic stress disorder, unrelated to our product pipeline, Bionomics' BNC210 is the only promising registrational stage program with a novel mechanism of action having demonstrated the best clinical study outcomes in decades, with a clear path for an NDA submission, and with one successful registrational quality study already competed, requiring one additional successful Phase 3 trial for potential registration. Of note, BNC210 also has two FDA fast track designations for SAD and PTSD programs, a sizable and favorable safety database supporting a differentiated non-sedating, non-addicting profile and positive datasets in four separate anxiety and stress-related indications. These clinical datasets and designations give us the ability to leverage regulatory privileges that can potentially accelerate review and approval. Moreover, we are also considering submitting a rebuttal in the future regarding the FDA decision to not grant a Breakthrough Designation in PTSD. It should also be noted that not being granted this designation does not in any way derail our progress or pathway in our clinical trials or intended operational success. As we continue executing the Phase 3 program in SAD with anticipated readout in Q3 2025, we are also working diligently on exploring ways to enhance efficiencies and foster potential partnerships that will ensure our ability to drive the Phase 3 trial of BNC210 in PTSD to a successful NDA submission with a single trial. This would be a major achievement for the Company following our successful End-of-Phase 2 meeting with the FDA in June 2024. We have begun trial initiation activities, and we are on track to commence the Phase 3trial in PTSD in the second half of 2025 or sooner, contingent upon successful financing. Our long-standing strategic partnership with MSD on the development of alpha7 receptor PAMs targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions valued ~$500M is quickly advancing and is anticipated to enter Phase 2 in the near future, triggering a sizable milestone payment for the Company. Along with you, we believe Bionomics has significant, unrealized value that is not yet reflected in the current stock price."

08:15 EDT NMI Holdings announces S&P rating upgrades - NMI Holdings announced that S&P Global Ratings has raised its long-term insurer financial strength rating on National Mortgage Insurance Corporation to "A-" and its issuer credit rating on NMI Holdings, Inc. to "BBB-". Both ratings carry a stable outlook.

08:13 EDT Monopar Therapeutics initiates Phase 1a trial for MNPR-101-Lu - Monopar Therapeutics announced that the Phase 1a clinical trial for its novel therapeutic radiopharmaceutical MNPR-101-Lu is now active and recruiting patients with advanced cancers. The Phase 1a trial is an open-label dose-escalation study of MNPR-101-Lu in patients with solid tumors. The first clinical trial site activated for the study is the Melbourne Theranostic Innovation Centre in Australia. To help identify those patients most likely to benefit from MNPR-101-Lu, the trial will only be open to those participating in the ongoing MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial. MNPR-101 is Monopar's proprietary antibody that targets the urokinase plasminogen activator receptor, which is expressed in numerous tumor types including pancreatic, breast, colorectal, ovarian, and bladder. By selectively targeting uPAR, Monopar aims to deliver a radiopharma therapy that kills cancer cells while minimizing damage to healthy tissue. Both clinical and preclinical data to date have demonstrated highly specific and durable tumor uptake of MNPR-101-Zr.

08:12 EDT Core Scientific earns 345 self-mined Bitcoin in September

08:09 EDT Infinera's XTM Series deployed by Poka Lambro to upgrade network - Infinera announced that Poka Lambro Telecommunications has deployed Infinera's XTM Series to upgrade its regional fiber broadband and middle-mile network across rural western Texas with ReConnect Program funding. With Infinera's solution, Poka Lambro can cost-efficiently deliver 400G services across the region to provide reliable middle-mile connectivity to support its own fiber broadband transport needs and those of other internet service providers and to connect historically underserved communities.

08:08 EDT Worksport targets cash flow positivity in 2025 - Worksport announced key strategic updates along with updates on upcoming product launches aiming to accelerate revenue growth. Strategic Initiatives" Targeting Cash Flow Positivity in 2025: With multiplying revenues and improving margins, the Company believes there is a path toward near-term enterprise profitability. Launching Three New & Highly Demanded Product Lines: Upcoming product lines are aimed at strengthening revenue pathways and brand presence of Worksport going forward. Expanding Market Reach: The Company aims to capitalize on the growing demand for its products within the three multi-billion-dollar markets it operates in. Streamlining Operations: The Company plans to implement targeted cost-saving measures in Q4, aimed to enhance margins and lower operational overhead without compromising growth. Steven Rossi, CEO of Worksport, added: "We are strategically positioned for continued growth and are committed to enhancing shareholder value. Our objective is to push for organic growth, and we reiterate our confidence in the Company's fundamentals and future prospects. With multiple high-demand products set for release and our ongoing innovations in clean energy, we are dedicated to executing our vision and look forward to sharing our progress with our shareholders."

08:06 EDT Leidos awarded $303M U.S. Air Force contract - Leidos was recently awarded a $303M contract to oversee planning, analysis, and operations for the Department of the Air Force's Advanced Battle Management System - Digital Infrastructure network, which is a core component of the DAF Battle Network. The contract was awarded by the DAF Program Executive Officer Command, Control, Communications and Battle Management and covers a three-year performance period, with two option years. As ABMS-DI network manager, Leidos will perform a wide range of management functions to support the successful standup of the Digital Infrastructure Network. This contract extends Leidos' collaborative role with the DAF to design, develop, and deploy modern combined Joint All-Domain Command and Control capabilities for the Air Force and Space Force.

08:04 EDT NextPlat gets four-year extension of OPKO Healthcare e-commerce program in China - NextPlat (NXPL)announced a significant expansion of its exclusive e-commerce distribution agreement with OPKO Health (OPK) for the online sales of its OPKO Health Europe products in China including securing a new four-year extension and approval to exclusively market its products in Japan. Under terms of the original exclusive e-commerce development program with OPKO, NextPlat launched a OPKO Health branded online storefront on Alibaba Group Holding Limited's (BABA) Tmall Global e-commerce platform in China featuring an assortment of nutraceutical and veterinary products sold and distributed by OPKO Europe. The original one-year exclusive contract has been extended for four years and expanded to include additional e-commerce platforms and digital and social media marketing across China. Additionally, the e-commerce development program was expanded to include the exclusive rights for the sales and marketing of OPKO products to potentially millions of consumers in Japan. According to Statista, Japan was the third largest e-commerce market with revenue exceeding $151B in 2023

08:03 EDT Walgreens Boots Alliance appoints Jason Stenta as chief commercial officer - Walgreens Boots Alliance announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. Stenta will begin his new role in early October.

08:02 EDT Akebia, U.S. Renal Care sign commercial supply contract - Akebia Therapeutics and U.S. Renal Care announced entry into a multi-year commercial supply contract encompassing all USRC dialysis centers. The contract enables USRC attending physicians to prescribe Vafseo for patients on dialysis as deemed clinically appropriate when it is expected to be available in January 2025. In March 2024, Vafseo was approved by the U.S. Food and Drug Administration for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. Akebia expects to receive Transitional Drug Add-on Payment Adjustment designation for Vafseo in January 2025.

08:01 EDT Concentra opens new medical center in Orlando - Concentra announced the opening of a new medical center in Orlando, Florida. The medical center, Concentra Orlando West, is conveniently located at 6708 Grand National Drive, Orlando, Florida 32819.

07:58 EDT ZyVersa Therapeutics forms Scientific Advisory Board - ZyVersa Therapeutics announces a new SAB to support advancement of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications. Based on its mechanism of action, IC 100, in combination with incretin therapy, is anticipated to augment weight loss, but more importantly, to attenuate the chronic systemic inflammation leading to metabolic complications and other inflammatory comorbidities of obesity. Members of ZyVersa's Obesity, Metabolic and Inflammatory Diseases SAB are listed. Caroline M. Apovian, MD, FACP, FTOS, DABOM Co-Director, Center for Weight Management and Wellness, Division of Endocrinology, Diabetes, and Hypertension at Brigham and Women's Hospital. Harold Bays, MD, MFOMA, FTOS, FACC, FACE, FNLA, FASPC Medical Director and President, Louisville Metabolic and Atherosclerosis Research Center. Helen Bramlett, PhD Professor, Department of Neurological Surgery, University of Miami Miller School of Medicine. Marc-Andre Cornier, MD Professor of Medicine, Medical University of South Carolina. W. Dalton Dietrich, III, PhD Kinetic Concepts Distinguished Chair in Neurosurgery, and Scientific Director. Robert W. Keane, PhD Professor, Physiology and Biophysics, Neurological Surgery and Microbiology, and Immunology, University of Miami Miller School of Medicine. Samuel Klein, MD William H. Danforth Professor of Medicine, Washington University School of Medicine. Suneil Koliwad, MD, PhD Chief, Division of Endocrinology and Metabolism, UCSF Health.

07:36 EDT Fury Gold Mines announces results from pegmatite outcrops at Eleonore South - Fury Gold Mines announced results from multiple lepidolite and spodumene-bearing pegmatite outcrops within the western claim block at its 100% owned Eleonore South gold project located in the Eeyou Istchee Territory in the James Bay region of Quebec. The outcrop sampling program targeted the historical Fliszar showing lepidolite bearing pegmatite as well as new rock exposures over an area of approximately 1000 x 500 metres resulting in the collection of 34 samples. Seven samples returned high-grade values above 1.75% lithium oxide with a peak value of 4.67% Li2O. "Eleonore South continues to be a high-priority project in our portfolio, with its multiple avenues for new discovery on the property. Today we are excited to include discoveries of high-grade lithium at the project," commented Tim Clark, CEO of Fury. "These results add to our confidence that we can continue to find new ways to add value to investors. At the moment, we are eagerly awaiting the results from our summer biogeochemical sampling program targeting the highly prospective Eleonore style anomaly at Eleonore South and the surficial sampling program conducted at Committee Bay."

07:33 EDT Algorhythm's SemiCab awarded service contract with global CPG company - Algorhythm Holdings has been awarded a service contract with a leading global beverage, food, and snack company. Under the agreement, Algorhythm's subsidiary, SemiCab Holdings, will provide enterprise-level shipping services through its AI-powered software platform, focusing on reducing empty truck miles. The contract, commencing mid-October 2024, will initially cover multiple large metropolitan markets, with the potential to rebid for additional lanes after six months.

07:29 EDT Beasley Broadcast announces expiration of exchange offer, tender offer - Beasley Broadcast announces the expiration and final results of its previously announced offers including an exchange offer of the Company's existing 8.625% Senior Secured Notes due 2026, a cash offer to purchase up to $68.0 million of Existing Notes at a purchase price of 62.5%, a new notes offer of $30.0 million aggregate principal amount of 11.000% Superpriority Senior Secured Notes due August 1, 2028, and the solicitation of consents of the terms and conditions set forth in the Exchange Offer Memorandum. In the Exchange Offer, holders of the Existing Notes, had the opportunity to exchange their holdings into: newly issued 9.200% Senior Secured Notes due August 1, 2028 at an exchange ratio of 95.0% of the aggregate principal amount of the Existing Notes tendered for exchange; a pro rata share of 179,424 shares of Class A Common Stock of the Company based upon pro rata ownership of the Exchange Notes, pursuant to the terms and conditions described in the Exchange Offer Memorandum and Consent Solicitation Statement, dated September 5, 2024 and a consent fee of $5.00, in each case per $1,000 principal amount of Existing Notes tendered. Subject to the terms and conditions set forth in the Exchange Offer Memorandum, the Company has the option to increase the Exchange Shares issued and/or the cash amount paid to each exchanging holder in the Exchange Offer by an amount not to exceed, in the aggregate, a pro rata portion of $3.0 million if, and to the extent the Company determines, in its sole discretion, that such issuance or payment would improve the Company's financial position after giving effect to the Exchange Offer, including the payment of fees and potential taxes associated therewith. The Company expects to make a final determination regarding an increase in the amount of Exchange Shares to be issued and/or cash to be paid to each exchanging holder shortly prior to settlement of the Exchange Offer on October 8, 2024.

07:25 EDT Solaris reports assay results from drill program at Warintza Project - Solaris Resources reports assay results from its ongoing 2024 drilling program of 60,000m targeting open extensions of mineralization while upgrading mineral resources and converting waste at its Warintza Project in southeastern Ecuador. Drill results reported here build on the 2024 Mineral Resource Estimate, with this release including intercepts of high-grade mineralization partially outside of the MRE in the northwest and northeast sectors. Holes in this release also improve upon modelled grades in sparsely drilled areas of the northwest, north and northeast sectors. Northwest, North and Northeast Sectors: SLS-102: 93m of 1.01% CuEq within 156m of 0.74% CuEq from surface; SLS-103: 87m of 1.23% CuEq within 528m of 0.59% CuEq from surface; SLS-104: 84m of 1.00% CuEq within 485m of 0.77% CuEq from surface; SLSE-54: 258m of 0.52% CuEq within 399m of 0.41% CuEq from surface; Holes SLS-103 and SLSE-54 added new high-grade mineralization at surface partially outside of the MRE in the northwest and northeast sectors, respectively, while all four holes improved upon the modelled grade in their vicinity. SLS-102 is located in the northwest sector where mineralization has been extended to the contact with a tabular granodiorite that shapes the northwestern pit wall. Step-out exploration drilling testing the potential for mineralization within a large area of undrilled soil anomaly on the far side of this body has been completed with assays expected in the coming weeks. Warintza continues to see high drilling productivity from significant infrastructure investment at site and is on track to exceed the 60,000m of drilling planned this year, with over 53,000m drilled to the end of Q3/24. Drilling includes holes focused on open extensions and infill of the MRE, as well as condemnation and geotechnical drilling.

07:18 EDT Gain Therapeutics presents preclinical data on GT-02287 - Gain Therapeutics announced the presentation of new evidence supporting the disease-modifying activity of GT-02287 in preclinical animal models of both GBA-1 and idiopathic Parkinson's disease during a late-breaker poster session yesterday at the Society for Neuroscience 2024 conference that is being held October 5-9 in Chicago, IL. In animal models of GBA-1 and idiopathic Parkinson's disease, rescue of motor and cognitive function associated with administration of GT-02287 was observed to be persistent upon wash out of GT-02287 without significant effect in performance for more than a week following discontinuation when compared to the animals in which treatment was continued. Another presentation for GT-02287 yesterday described its association with improved mitochondrial function and neuroprotection in GBA1-Parkinson's disease models. Finally, a second late-breaker was presented describing the reduction in Tau accumulation associated with GT-02287 in both GBA-1 mutation and wild type cell lines, suggesting GT-02287 may have broader potential as a treatment for tauopathies such as Alzheimer's disease. The late-breaking poster titled, "GT-02287, a clinical stage GCase regulator, demonstrates disease modifying capacity in both GBA1 and idiopathic Parkinson's disease models," was presented on-site October 6 at 3pm CT. In animal models of both GBA1 and idiopathic Parkinson's disease, GT-02287 was administered after a clinical phenotype was established and then withdrawn from half the animals for more than one week prior to conclusion of the study. Neuromuscular function, motor coordination, and activities of daily living/cognition were measured in wire hang, beam walk, and nest building tests, respectively, throughout the study. GT-02287 was shown to rescue deficits in neuromuscular function and motor coordination in both models as well as to prevent the development of deficits in cognition and activities of daily living. Notably, withdrawal of GT-02287 for more than one week did not significantly affect performance in any of the tests, suggesting a disease modifying effect. The poster titled, "GT-02287, a clinical stage GCase regulator, improves mitochondrial function and provides a neuroprotective effect in GBA1-Parkinson's disease models," was presented on-site October 6 at 10am CT. In an in vitro model - in which cultured rat mesencephalic dopaminergic neurons were treated with conduritol beta epoxide to cause partial knockdown of GCase activity comparable to that seen in PD patients carrying heterozygous GBA1 mutations- treatment with GT-02287 reduced the level of mitochondrial reactive oxygen species as well as ameliorating lysosomal pathology, reducing alpha-synuclein aggregation, and providing a neuroprotective effect. In an in vivo model in which mice were subjected to toxic insult by CBE and injection of alpha-synuclein preformed fibrils into the striatum - delayed administration of GT-02287 reduced levels of mitochondrial protein Miro1, an important maker for mitophagy; aggregated alpha-synuclein and plasma neurofilament light chain, a marker of neurodegeneration; as well as completely restoring motor function to control levels. The late-breaking poster titled, "GT-02287, a GCase modulator and Gain Therapeutics' PD drug candidate prevents Tau accumulation in a cellular model," was presented on-site October 6 at 1pm CT. Lysosomal Tau accumulation was quantified in human fibroblasts, carrying either the L444P mutant or wild-type GBA engineered to express labelled Tau protein, at basal conditions as well in the presence of Alzheimer's brain-derived Tau seeds. Basal and seed-induced Tau accumulation was significantly higher in Tau-GBA L444P cells, which express defective GCase, compared to Tau WT GBA cells. Treatment with GT-02287 reduced Tau accumulation in both cells carrying the L444P GBA mutation and those carrying wild-type GBA, demonstrating GT-02287's potential as a disease-modifying treatment for Alzheimer's disease and other tauopathies. This work was carried out in collaboration with scientists in the group of Professor Paolo Paganetti at the Laboratories for Translational Research of the Ente Ospedaliero Cantonale in Bellinzona, Switzerland. This study was conducted under the support of an Innosuisse-Swiss Innovation Agency grant with the LRT-EOC and the Universita della Svizzera italiana-affiliated Institute for Research in Biomedicine in Bellinzona, Switzerland.

07:16 EDT Gray Media announces Local New Live launches standalone streaming apps - Gray Media announced that Local News Live, its 24/7 streaming news network, launched standalone apps for connected TVs and smartphones. These new apps are now available to download for free by searching "LNL" on Roku, Amazon Fire, Apple TV, iOS, and Android streaming devices.

07:14 EDT OTC Markets welcomes Generations Bancorp NY to OTCQX - OTC Markets Group announced Generations Bancorp NY, the holding company for Generations Bank, has qualified to trade on the OTCQX Best Market. Generations Bancorp NY, Inc. previously traded on NASDAQ.

07:13 EDT Niu Technologies launches KQi 100F electric scooter in U.S. - Niu Technologies announced the U.S. launch of its latest product, the KQi 100F kick scooter, at the upcoming Electrify Expo in New York. The event will take place at Citi Field on October 12-13, 2024, marking the first time U.S. consumers will experience the KQi 100F, a powerful, sustainable solution for urban transportation. The KQi 100F will launch in Best Buy November 1, including Best Buy Partner+ which allows customers to enjoy same day in-store pickup and checkout via Shopify. The KQi 100F has an MSRP of $449. The KQi 100P, which made its debut at Walmart retailers last month and will be in Kohl's beginning in November, will also be at Electrify Expo New York for consumers to test ride.

07:11 EDT Virios Therapeutics, Wex Pharmaceuticals announce 25-for-1 reverse stock split - In connection with the Combination, the Company is announcing a reverse split of 25-for-1. The reverse stock split will be effective on October 9, 2024, resulting in outstanding shares of common stock of 1,110,317 prior to the issuance of shares pursuant to the share exchange agreement. The 25-for-1 reverse stock split will automatically result in the conversion of twenty-five current shares of the Company's common stock into one new share of common stock. No fractional shares will be issued in connection with the reverse stock split. In lieu thereof, each stockholder who would be entitled to receive a fractional share will be entitled to receive a cash payment equal to the fair market value of such fractional share. The Company expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on October 9, 2024 with a new CUSIP number of 92829J203 and under the symbol "DWTX".

07:09 EDT Virios Therapeutics, Wex Pharmaceuticals announce business combination agreement - Virios Therapeutics and Wex Pharmaceuticals announced that Virios has entered into a definitive share exchange agreement with Sealbond Limited, an indirect parent of Wex, pursuant to which the companies will combine in an all-stock transaction. The combined company's new name will be Dogwood Therapeutics and it will be focused on the clinical development of three assets: Halneuron, currently in Phase 2b development for chemotherapy-induced neuropathic pain; IMC-1, poised for Phase 3 development as a treatment for fibromyalgia; and IMC-2, currently in Phase 2 development to treat Long-COVID sequelae. In connection with the Combination, the Company announced that it is raising $19.5 million in a committed debt financing by an affiliate of CKLS in two tranches with $16.5 million funding at closing and an additional $3 million funded in 1Q25, subject to certain customary conditions. This financing is expected to fund research and operations through several key milestones, including the release of results from the Halneuron Phase 2b interim analysis assessment expected in 2H25. Dogwood will be led by industry veterans, including Chief Executive Officer Greg Duncan; Chief Medical Officer Mike Gendreau, M.D., PhD; Senior Vice President Operations Ralph Grosswald; Chief Financial Officer Angela Walsh and Vice President Manufacturing Meng Zhou. The combined Board of Directors consists of Rick Keefer; John Thomas; Richard Whitely, MD; Abel De La Rosa, PhD; Alan Yu; Melvin Toh, MBBS; and Chairman Greg Duncan. Effective October 9, 2024, the Company will change its name from "Virios Therapeutics, Inc." to "Dogwood Therapeutics, Inc." The Company's common stock will cease trading under the ticker symbol "VIRI" and will begin trading on the Nasdaq Capital Market under the ticker symbol "DWTX" as of the commencement of trading on October 9, 2024. Halneuron is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor to treat the neuropathic pain associated with chemotherapy treatment. Halneuron has been granted Fast Track Designation from the FDA for the treatment of CINP. Next milestone: Interim data from the ongoing Phase 2 CINP study are expected in 2H25. IMC-2 is in Phase 2 development as a combination antiviral treatment for Long-COVID. Next milestone: Topline data from an investigator led, double blind controlled proof of concept study, assessing two doses of IMC-2 vs placebo, are expected in early 4Q24. IMC-1 is Phase 3 development ready as a combination antiviral treatment for FM. IMC-1 has been granted fast track designation by the FDA. Next milestone: Dogwood is exploring partnerships for IMC-1 to execute the Phase 3 FM program as agreed with the FDA. Pursuant to the definitive share exchange agreement, immediately following the reverse stock split, Sealbond, the sole stockholder of Wex and an indirect wholly-0wned subsidiary of CKLS, will receive an aggregate of 211,383 shares of common stock and 2,108.3854 shares of non-voting convertible preferred stock which represents, on a fully diluted basis, approximately 94% for Sealbond and approximately 6% for the pre-Combination stockholders of Virios Therapeutics and a combined fully diluted equity value of approximately $105 million. In connection with the Combination, the Company entered into a loan agreement with an affiliate of CKLS for a cash investment of $19.5 million, which will be funded in two tranches with $16.5 million funded at closing and an additional $3 million funded in 1Q25, subject to certain customary conditions. The issuance of shares of common stock upon conversion of the Preferred Stock issued in the Combination shall be subject to stockholder approval in compliance with the rules of the Nasdaq Stock Market. A non-transferrable CVR will be distributed to Dogwood stockholders of record as of October 17, 2024 to receive certain proceeds received by Dogwood, if any, related to future upfront, development or regulatory milestone payments resulting from corporate partnering transactions of IMC-1 and IMC-2.

07:07 EDT AerCap purchased and sold 226 assets in Q3 - AerCap Holdings (AER) has announced its major business transactions during the third quarter 2024: Signed 160 lease agreements, including 13 widebody aircraft, 107 narrowbody aircraft, 24 engines and 16 helicopters. Completed 41 purchases for 27 aircraft (including 2 Airbus (EADSY) A220 Family aircraft, 18 Airbus A320neo Family aircraft, 4 Boeing (BA) 737 MAX aircraft, 1 Boeing 787-9 and 2 Embraer (ERJ) E195-E2s for AerCap's owned aircraft portfolio), 13 engines and 1 helicopter. Completed 25 sale transactions for 18 aircraft (including 5 Airbus A320 Family aircraft, 3 Airbus A320neo Family aircraft, 4 Boeing 737NGs, 1 Boeing 767-300ER, 1 Boeing 777-300ER and 4 Embraer E190s from AerCap's owned aircraft portfolio), 3 engines from AerCap's managed engine portfolio and 4 helicopters. Signed financing transactions for approximately $10.5 billion, including $2.4 billion of senior unsecured notes. Repurchased approximately 5.5 million shares, at an average price of $91.03 per share, for a total of approximately $497 million. Paid quarterly cash dividend on ordinary shares of $0.25 per share.

07:05 EDT Cytomed Therapeutics announces NMRC co-funding support for ANGELICA trial - CytoMed Therapeutics has obtained full approval for its first-in-human Phase I clinical trial using its patented allogeneic chimeric antigen receptor T cell against several blood and solid tumors in collaboration with the National University Hospital of Singapore. The ANGELICA Trial is co-supported by the Singapore Ministry of Health through the National Medical Research Council Office, and MOH Holdings Pte Ltd under the NMRC Clinical Trial Grant Industry Collaborative Trials scheme. Grant details are confidential. CAR-T cell therapy is currently an individualised treatment that typically involves taking a patient's blood cells and modifying these in the laboratory by grafting an artificial protein, known as a chimeric antigen receptor, on the surface of T cells, a type of white blood cells. The modified T cells are then re-infused into the patient to target and destroy cancer cells. Unlike chemotherapy which targets all actively dividing cells including healthy ones, CAR-T cells specifically recognise targets present on cancer cells to kill them, thus sparing healthy cells. The ANGELICA Trial taps on blood drawn from young healthy donors, potentially improving the quality of CAR-T cells manufactured, lowering production costs and increasing patients' timely access to therapy since they can be produced off-the-shelf en masse. Current established CAR-T cell therapies use alpha-beta T cells, a type of immune cells which are largely non-transferable between individual human beings due to the high risk of graft-versus-host disease where the graft attacks the host. CytoMed's ANGELICA Trial uses a rare subtype of immune cells known as gamma delta T cells which can be modified from healthy donors and re-infused into un-related patients without the need for matching. The ANGELICA Trial comprises two parts. Part 1 is ongoing with the recruitment of healthy blood donors at NUH. With the continued collaboration between CytoMed Therapeutics and NUH, Part 2 of the trial may now proceed with the recruitment of patients who have advanced cancers that are resistant to standard therapy regimens. On a separate note, CytoMed has taken over the assets and licence of a licenced cord blood bank in Malaysia using internal cash resources. Please refer to CytoMed's announcement on July 17, 2024 and October 3, 2024. This acquisition will sharpen CytoMed's strategy in cell therapies as it now has access to rare and precious cord blood donated for research and development. There is abundant clinical evidence on cord blood-derived biologics for a wide range of aging diseases and regenerative medicine. This new biotechnology arm will be undertaken through CytoMed's subsidiary, LongevityBank Pte Ltd. The latter is the holding company of IPSC Depository Sdn Bhd which holds the cord blood banking licence issued by the Ministry of Health, Malaysia.

07:03 EDT Albemarle names Netha Johnson COO amid operating structure transition - Albemarle announced the company's new operating structure. Albemarle's operating structure will transition from two core global business units - Energy Storage and Specialties - to a fully integrated functional model designed to increase agility, deliver cost savings and maintain long-term competitiveness. The move is the next step in the company's review of its cost and operating structure. Specialties Business President Netha Johnson will become chief operations officer and continues to report to chairman and CEO Kent Masters. In this role, he will lead global manufacturing, research and technology, capital projects and process chemistry execution. Johnson joined Albemarle in 2018 and has more than 25 years of experience in global manufacturing, leadership and general management. Energy Storage Business president Eric Norris will become chief commercial officer and continues to report to Masters. In this role, he will oversee enterprise product management, sales and commercial excellence. Norris joined Albemarle in 2018 and has more than 25 years of experience in strategy, corporate development and general management. Melissa Anderson will become chief transformation officer, effective November 1, which reflects her current oversight of people, strategy and transformation. Stacy Grant will become general counsel, corporate secretary and chief compliance officer, effective immediately, and succeeds Kristin Coleman, who is leaving the company. Grant joined Albemarle in 2023 and previously served as vice president & deputy general counsel, global corporate affairs. Cynthia Lima remains chief external affairs and communications officer and will add oversight responsibility for product stewardship. Mark Mummert will become chief capital, resources and integrated supply chain officer, effective November 1, which includes expanded responsibility for resources, joint venture management, customer service and operational excellence. Neal Sheorey remains chief financial officer and will add oversight responsibilities for information technology, global business services and real estate. Albemarle will continue to report results across its three existing operating segments: Energy Storage, Specialties and Ketjen.

06:59 EDT UniFirst opens advanced uniform service, processing facility in New York - UniFirst announced the grand opening of its advanced uniform service and processing facility in Liverpool, New York. This investment highlights UniFirst's ongoing commitment to serving the Syracuse market. The newly built 65,000-square-foot facility replaces the previous smaller structure on the same site, completing a three-year transition without interrupting service for its more than 2,000 local customers throughout the central New York region. The facility offers a range of services, including uniform rental and facility services, hygienic laundering, maintenance, and pickup and delivery.

06:56 EDT Genco Shipping to acquire high-specification Capesize vessel for $47.5M - Genco Shipping & Trading has agreed to acquire a 2016-built 180,000 dwt high-specification Capesize vessel for a purchase price of $47.5M. Genco expects to take delivery of the vessel, to be named the Genco Intrepid, within the next 30 days, and intends to fund the acquisition with cash on hand and a drawdown from its revolving credit facility.

06:54 EDT Meihua regains compliance with Nasdaq - Meihua announced that on October 3, it received a notification letter from the Listing Qualifications Department of the Nasdaq, informing the company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450.

06:47 EDT Barnes Group to be acquired by Apollo Global for $47.50 per share in cash - Barnes Group (B) announced that it has entered into a definitive agreement to be acquired by funds managed by affiliates of Apollo Global (APO) in an all-cash transaction that values Barnes at an enterprise value of approximately $3.6B. The agreement provides that Barnes shareholders will receive $47.50 per share in cash. The per share purchase price represents a premium of approximately 22% over Barnes' undisturbed closing share price on June 2, and a premium of approximately 28% over the volume weighted average price of Barnes common stock for the 90 days ending June 25. The transaction is expected to close before the end of Q1 2025 and is subject to customary closing conditions, including approval by Barnes shareholders and receipt of required regulatory approvals. The Barnes board of directors unanimously approved the definitive agreement and recommends that Barnes shareholders vote in favor of the transaction. Upon completion of the transaction, Barnes will be delisted from the New York Stock Exchange and become a privately held company. Barnes will continue to operate under the Barnes Group name and brand.

06:45 EDT Barnes Group to be acquired by Apollo Global funds for $3.6B

06:33 EDT Rocket Lab awarded contract from NASA - Rocket Lab announced the company has been selected by NASA to complete a study for retrieving rock samples from the Martian surface and bringing them to Earth for the first time. The mission would fulfill some of the highest priority solar system exploration goals for the science community - to revolutionize humanity's understanding of Mars, potentially answer whether life ever existed on the Martian surface, and help prepare for the first human explorers to the Red Planet. NASA's Rapid Mission Design Studies for Mars Sample Return solicits industry proposals to carry out rapid studies of mission designs and mission elements capable of delivering samples collected by the Mars Perseverance rover from the surface of Mars to Earth. The results of this study will inform a potential update to NASA's Mars Sample Return Program and may result in future procurements with industry. Rocket Lab's study will explore a simplified, end-to-end mission concept that would be delivered for a fraction of the current projected program cost and completed several years earlier than the current expected sample return date in 2040.

06:18 EDT American Water announces 'unauthorized activity within its computer networks' - In a regulatory filing, American Water stated, "On October 3, 2024, American Water Works Company learned of unauthorized activity within its computer networks and systems, which the company determined to be the result of a cybersecurity incident. Upon learning of this activity, the company immediately activated its incident response protocols and third-party cybersecurity experts to assist with containment and mitigation activities and to investigate the nature and scope of the incident. The company also promptly notified law enforcement and is coordinating fully with them. The company has taken and will continue to take steps to protect its systems and data, including disconnecting or deactivating certain of its systems. The company currently believes that none of its water or wastewater facilities or operations have been negatively impacted by this incident. Although the company is currently unable to predict the full impact of this incident, the company does not expect the incident will have a material effect on the company, or its financial condition or results of operations."

06:05 EDT Hooker Furniture signs global licensing agreement with Margaritaville - Hooker Furnishings has entered into a licensing agreement with Margaritaville to launch an extensive line of home furnishings that spans various price points and categories. The partnership will include a range of indoor and outdoor furnishings including case goods, upholstery, lighting, and accessories for the residential, contract, and hospitality markets. The agreement includes the flagship Margaritaville brand, as well as Latitude by Margaritaville and Island Reserve by Margaritaville, creating tiered product differentiation that aligns well with Hooker Furnishings' versatile brand portfolio. The planned launch of the complete indoor/outdoor whole home collection will be in October 2025 at Hooker Furnishings' Showplace showroom in High Point, NC. Additionally, plans to explore hospitality and commercial opportunities, providing furnishing options for Margaritaville's branded real estate properties and communities are underway.

05:34 EDT Chevron Canada to sell interest in the Athabasca Oil Sands Project for $6.5B - Chevron Canada, an indirect subsidiary of Chevron, announced that it and a related entity have entered into a definitive agreement to sell their 20% non-operated interest in the Athabasca Oil Sands Project, 70% operated interest in the Duvernay shale, and related interests, all located in Alberta, Canada, to Canadian Natural Resources. The $6.5B all-cash transaction has an effective date of September 1 and is expected to close during the fourth quarter of 2024, subject to regulatory approvals and other customary closing conditions. The assets subject to the agreement contributed 84,000 boe/d of production, net of royalties, to Chevron in 2023. This transaction progresses Chevron's previously announced plans to divest $10B-$15B in assets by 2028 to optimize its global energy portfolio.

05:29 EDT Richemont to sell YNAP to Mytheresa - Mytheresa and Richemont announced that they have entered into binding agreements for the acquisition of 100% of the share capital of YNAP by Mytheresa. The transaction aims to create a group offering an edit of the most prestigious luxury brands and products to luxury enthusiasts worldwide. The transaction entails the separation of the off-price division from the Luxury division and the discontinuation of YNAP's white label division, once the Richemont Maisons' online stores powered by YNAP migrate to their own chosen platforms. At transaction closing, Richemont will sell YNAP to Mytheresa with a cash position of EUR 555M and no financial debt, subject to customary closing adjustments, in exchange for shares to be issued by Mytheresa representing 33% of Mytheresa's fully diluted share capital at closing following issuance of the consideration shares. Richemont will make available a six-year revolving credit facility of EUR 100M to finance YNAP's general corporate needs, including working capital. Richemont will have the right to nominate a member and an observer to the Supervisory Board of Mytheresa following closing. Closing of the transaction, which is expected to occur in the first half of calendar year 2025, is subject to customary conditions, including the receipt of antitrust approvals. The transaction is not subject to or conditional on approval by either Richemont or Mytheresa shareholders. Richemont's shareholding in Mytheresa will be subject to a one-year lock-up period following transaction closing, followed by a further one-year period in which only certain limited sale transactions may take place. As a result of this transaction, Richemont currently expects the write-down of YNAP net assets to amount to approximately EUR 1.3B, which also accounts for the cash to be left in YNAP upon completion. This value is subject to change until completion date as it depends on several variables, namely Mytheresa's share price, the USD/EUR foreign exchange rate, the value of net assets and debt-like items of YNAP at completion date.

05:19 EDT Epam Systems to acquire First Derivative, terms undisclosed - Epam Systems announced its agreement to acquire First Derivative, a Northern Ireland-headquartered managed services and consulting business for the capital markets industry with more than 1,800 employees worldwide and major delivery capability in the U.K., Ireland, North America and APAC. EPAM will leverage First Derivative's industry experience and brand to deliver a set of AI-enabled end-to-end capabilities to clients in banking, capital markets and other financially regulated businesses across North America, Europe and APAC. Through the acquisition, First Derivative will bring more than 100 new clients under the EPAM umbrella, offering unmatched value and setting a new standard for technology services in the financial services industry. First Derivative is a division of FD Technologies plc, which is listed on the Alternative Investment Market of the London Stock Exchange. The acquisition is subject to customary closing conditions, including the receipt of necessary regulatory clearances, and is expected to close in the fourth quarter of 2024. Stone Key Partners served as the exclusive financial advisor and Faegre Drinker served as the legal advisor to EPAM.

05:13 EDT Paysafe announces strategic partnership with GiG - Paysafe announced a strategic partnership with Gaming Innovation Group, or GiG, a B2B iGaming technology company. Under the agreement, Paysafe becomes the GiG-endorsed payments platform for all UK, continental European, North American and Latin American operators integrating its CoreX solution. Launched by GiG in January, CoreX is an AI-driven player account management platform serving online casino and sports-betting brands, giving operators the flexibility to localize their operations to any regulated jurisdiction. GiG's global reach will be further strengthened by integrating the processing capabilities of Paysafe's local payment methods.

05:08 EDT Hansa Biopharma announces results from NICE-01 trial 12-month follow up analysis - Hansa Biopharma announced results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the company's next generation immunoglobulin G-cleaving molecule, assessing IgG recovery, immunogenicity and redosing potential. In the NICE-01 trial, HNSA-5487 demonstrated reduction of IgG levels by more than 95% within a few hours post treatment. In a 12-month follow up analysis IgG levels returned to normal range six months after initial dosing. This confirms that HNSA-5487 mirrors the extremely high efficacy of imlifidase, the company's first-generation IgG-cleaving enzyme, in reducing total IgG levels. No serious adverse events were observed and as previously communicated HNSA-5487 is safe and well tolerated. Importantly, HNSA-5487 demonstrated lower pre-treatment anti-drug antibody levels and significantly reduced ADA responses when compared to imlifidase, confirming an attractive immunogenicity profile with a clear redosing potential. HNSA-5487 also demonstrated highly robust reduction in IgG levels with similar efficacy in nearly 100 percent of serum samples collected in the trial and analyzed at six- and 12-months after the initial dose.